Alnylam Pharma (ALNY 203.97, +3.90, +2.0%): announces partnership with Roche (RHHBY) to co-develop and co-commercialize Zilebesiran
Kodiak Sciences (KOD 3.51, -3.78, -51.9%): announces topline results from its Phase 3 studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and provides update on tarcocimab development program